Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $389.0M | +263.6% | $-1.34B | $-3.40 | -34.9% | -145.5% | -356.8% |
| Q4 2025 Dec 2025 | $676.0M | — | $-826.0M | $-2.11 | — | 33.1% | -126.8% |
| Q3 2025 Sep 2025 | $1.00B | — | $-200.0M | $-0.51 | — | 79.3% | -26.0% |
| Q2 2025 Jun 2025 | $137.0M | — | $-825.0M | $-2.13 | — | 13.1% | -662.0% |
| Q1 2025 Mar 2025 | $107.0M | — | $-971.0M | $-2.52 | — | 15.9% | -981.3% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Can the Moderna Flu Vaccine turn an FDA panel win into a real growth story before Wall Street loses patience? Maik Kemper Editor in Chief The 9–0 VRBPAC…
